In the article by Choudhury and Kantoff titled “New Agents in Metastatic Prostate Cancer” published in the November 2012 issue of JNCCN (2012;10:1403-1409) an error occurred in the text on page 1406.

In the last paragraph of the “Immunotherapy” section, the first sentence should have read:

“Another agent currently being studied in a phase III trial (PROSPECT; ClinicalTrials.gov identifier: NCT01322490) is PROSTVAC-VF/TRICOM, a tumor vaccine composed of 2 recombinant viral vectors (a vaccinia-based vector for priming and a fowlpox-vector for subsequent boosting), each encoding transgenes for PSA in addition to 3 immune costimulatory molecules (B7.1, ICAM-1, and LFA-3).

The authors and editorial office apologize for this error. A corrected copy of the article is available online at JNCCN.org.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Article Information

PubMed


Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 5 5 0
PDF Downloads 3 3 0
EPUB Downloads 0 0 0